AVID Medical pulls convenience kits after fungal contamination concern tied to BD ChloraPrep applicators
The FDA has classified AVID Medical’s convenience kit action as a Class I recall, the agency’s most serious recall designation. The affected products are certain kits that contain recalled BD ChloraPrep applicators and may carry a contamination risk under specific environmental conditions that could allow Aspergillus penicillioides to grow.
This is not a narrow paperwork correction. The recall directs hospitals, distributors, and other purchasers to remove affected kits from use or sale, quarantine inventory, and destroy the entire kit after completing the required response forms.
Why the entire kit is now being destroyed
The update changes the response from the earlier instruction tied to AVID Medical’s July 22 notification. At that time, affected convenience kits were to be over-labeled so users would remove and discard the implicated component before use. The revised action is more aggressive: the entire kit should be destroyed for the products named in this communication because of potential contamination.
The practical reason is straightforward. Convenience kits are assembled to streamline bedside preparation for procedures, and the skin antiseptic component sits inside a bundled set of supplies that may be opened and deployed in time-sensitive settings. Once contamination is possible, partial salvage no longer offers a clean safety margin. Any fungal contamination inside a prep product can undermine the sterile chain before a procedure even begins.
The device and lot affected
The affected item named in the communication is the IV START KIT NON-STERILE, KIT with model/item number AVID KIT KRIV26-02, kit lot number 1658437, and UDI 10809160460481.
AVID Medical said the kits were previously identified in an earlier notification, but additional recall details from BD led to a change in the required action for the items listed in this update. The BD product involved in the broader issue is the ChloraPrep Clear 1 mL Single Sterile applicator, identified by BD lot 4032183.
The clinical hazard is bloodstream infection, sepsis, and procedural escalation
Skin preparation products are supposed to reduce microbial burden before invasive care. When that barrier fails, the contamination risk extends beyond a superficial infection concern. In this case, the FDA communication states that contamination with Aspergillus penicillioides may lead to serious adverse health consequences, including systemic infection, sepsis, illness, and death.
If the fungus is introduced into the bloodstream during placement of an intravascular catheter, the catheter would likely need to be removed. That can force an additional procedure, extra vascular access attempts, and more exposure for patients already undergoing invasive care. When infection seeds a surgical site, the consequences can be even more disruptive: operative intervention, medical treatment, and long-term antifungal therapy may follow.
A contaminated prep applicator can therefore change the entire procedural trajectory. A routine line placement or operative prep becomes a potential infection event with downstream treatment burdens.
What facilities are being told to do now
Health care facilities are being instructed to review stock, quarantine affected convenience kits, and destroy them once the response form is completed. Distributors and anyone who resold or transferred the product must notify downstream recipients and ask them to destroy affected inventory as well.
The communication also warns that some of these kits may carry over-labels from the earlier notification, instructing users to remove and discard the affected component at the point of use. Those earlier instructions no longer apply to the specific items covered by this update. For these kits, the entire product should be destroyed.
This kind of recall management matters because convenience kits often move quickly through supply chains and procedural areas. A product that sits in a central sterile store, a pre-op area, or a catheter insertion cart can be easy to overlook unless inventory review is explicit and immediate.
No injuries have been reported, but the risk threshold is high
As of August 20, AVID Medical had not reported any serious injuries or deaths tied to this issue. Even so, the FDA still classifies the recall as most serious because the potential harm is severe enough to justify urgent removal from circulation.
That mismatch between reported injury count and recall class is common in device safety work. A dangerous contamination problem does not need a long trail of confirmed harm before regulators act, particularly when the product is designed for direct patient contact during invasive procedures. Prevention is the point.
The timeline shows the FDA issued an Early Alert on August 28, 2026, and later updated the communication on October 14, 2026 to classify the issue as a Class I Recall. The escalation signals how quickly a contamination concern can move from precautionary notice to formal high-risk recall status once the scope is clarified.
The broader lesson for procedural safety teams
The issue reaches beyond one lot number. Every convenience kit that bundles antisepsis, dressings, and procedure components depends on the integrity of each part inside the package. A single recalled component can compromise the entire set, and a contamination risk involving fungal growth is especially concerning because these organisms can be difficult to contain once introduced into a vulnerable procedural environment.
Hospitals and ambulatory centers that rely on preassembled kits for vascular access and other bedside procedures should treat the inventory review as a patient safety task, not a purchasing exercise. The recall notice directs customers to complete response forms, quarantine the affected product, and destroy it. Those steps are designed to keep contaminated material out of clinical circulation before a patient encounters it.
Customers in the U.S. with adverse reactions, quality problems, or questions are directed to contact AVID Medical at [email protected]. FDA reporting routes remain available through MedWatch for health care professionals and consumers who experience device-related problems.
The unresolved issue is how broadly the contamination concern extends across any related inventory beyond the lot specifically named here, which is why the recall process relies on traceability, quarantine, and destruction rather than product rework or relabeling.